HITOSHISUZUKI UrayasushiJapan

Wcn26 Post edited Speaker Card

29 March 2026

Time

Session

5 p.m.

6 p.m.

Industry Symposium 27

HITOSHISUZUKI Chair shitoshi@juntendo.ac.jpJapan

Welcome & Introduction

HITOSHISUZUKI Speaker shitoshi@juntendo.ac.jpJapan
Understanding IgA Nephropathy Worldwide: Presentation, Progression, and Epidemiology

ShikhaWadhwani Speaker shikha.wadhwani@northwestern.eduUnited States
Mechanistic insights: Exploring the Role of Complement in IgA Nephropathy

Jonathan Barratt Speaker jb81@leicester.ac.ukUnited Kingdom
Panel Discussion and Q&A Session & Closing Remarks

HITOSHISUZUKI Speaker shitoshi@juntendo.ac.jpJapan

304

30 March 2026

Time	Session

8:10 a.m. 9:10 a.m.	Industry Symposium 36 HITOSHISUZUKI Chair shitoshi@juntendo.ac.jpJapan Overview of Unmet Need in IgA Nephropathy and Disease Markers AdrianLiew Speaker draliew2@gmail.comSingapore Emerging Therapeutics Targets in IgAN: The Role of BAFF and APRIL SuceenaAlexander Speaker suceena@gmail.comIndia Targeting BAFF and APRIL with Atacicept RichardLafayette Speaker czar@stanford.eduUnited States 501 - 502
12:50 p.m. 1:50 p.m.	Industry Symposium 47 BradRovin Chair rovin.1@osu.eduUnited States Intro + IgAN Case: Global Perspective BradRovin Speaker rovin.1@osu.eduUnited States IgAN Case: China Perspective HongZhang Speaker hongzh@bjmu.edu.cnChina IgAN Case: Japan Perspective HITOSHISUZUKI Speaker shitoshi@juntendo.ac.jpJapan 301 - 302
5 p.m. 6 p.m.	Industry Symposium 58 HITOSHISUZUKI Chair shitoshi@juntendo.ac.jpJapan Tonsillectomy for IgA nephropathy MikiTakahara Speaker miki@asahikawa-med.ac.jpJapan Impact of Intestinal Barrier Dysfunction on IgA Deposition in the Glomeruli KojiHase Speaker hase.a6@keio.jpJapan 503